SAP gains on cloud strength, NVO faces obesity setbacks, and TMO leans on AI and innovation amid macro headwinds.

Hims and Hers announced this morning that it will begin offering compounded semaglutide (generic Ozempic or Wegovy) for $199 ...

The weight-loss drug boom has dominated headlines for the last two years — but underneath the hype lies a major flaw in the ...

Hims & Hers Health, Inc. (HIMS) announced on Wednesday that it will expand to Canada next year with its weight loss program, ...

Would you get a one-time genetic modification such that you'd never have to take a GLP-1 drug for weight loss ever again?

For weight loss, weight management, and overall wellness, focus on eating healthy foods, like high-protein meals, legumes, ...

GLP-1 drugs alter taste perceptions, challenging food makers to adapt by enhancing umami flavours, balancing sweetness, and ...

Hims & Hers announced plans to expand its weight loss program to Canada in 2026 in connection with the availability of generic semaglutide anywhere in the world.

Hims and Hers Health is planning to cash in on Novo Nordisk losing its semaglutide drug exclusivity in Canada. The telehealth ...

A study in Diabetes, Obesity and Metabolism has identified certain characteristics that might influence people's weight loss ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

ProKidney shares surged 500% on positive Phase 2 CKD results. Read why I remain cautious about PROK stock despite the recent ...